{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04811560",
            "orgStudyIdInfo": {
                "id": "CR108998"
            },
            "secondaryIdInfos": [
                {
                    "id": "2020-005967-30",
                    "type": "EUDRACT_NUMBER"
                },
                {
                    "id": "75276617ALE1001",
                    "type": "OTHER",
                    "domain": "Janssen Research & Development, LLC"
                },
                {
                    "id": "2023-506581-31-00",
                    "type": "REGISTRY",
                    "domain": "EUCT number"
                }
            ],
            "organization": {
                "fullName": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia",
            "officialTitle": "A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-phase-study-of-bleximenib-in-participants-with-acute-leukemia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-05-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-02-16",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-10-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-03-22",
            "studyFirstSubmitQcDate": "2021-03-22",
            "studyFirstPostDateStruct": {
                "date": "2021-03-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\\[s\\]) of bleximenib in phase 1 (Part 1 \\[Dose Escalation\\] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Leukemias",
                "Acute Myeloid Leukemia",
                "Acute Lymphoblastic Leukemia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 350,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Bleximenib",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in Phase 1 Part 1 (dose escalation) will receive bleximenib orally. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) have been identified. Participants in Phase 1 Part 2 (dose expansion) will receive bleximenib orally at the RP2D(s) determined in Part 1. Food effect cohort (optional) participants will receive bleximenib orally on Cycle 2 Day 1 under fasted condition and on Cycle 2 Day 2 under fed condition. Participants in Phase 2 part of the study will receive bleximenib orally at the RP2D level(s).",
                    "interventionNames": [
                        "Drug: Bleximenib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Bleximenib",
                    "description": "Bleximenib is administered orally.",
                    "armGroupLabels": [
                        "Bleximenib"
                    ],
                    "otherNames": [
                        "JNJ-75276617"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability",
                    "description": "An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 1: Number of Participants with AEs by Severity",
                    "description": "Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 1: Part 1: Percentage of Participants with Dose-Limiting Toxicity (DLT)",
                    "description": "Percentage of participants with DLT will be assessed accordingly to national cancer institute common terminology criteria for adverse events (NCI CTCAE) version 5.",
                    "timeFrame": "Up to 28 days Cycle 1"
                },
                {
                    "measure": "Phase 2: Rate of Complete Remission or Complete Remission with Partial Hematologic Recovery (CR/CRh)",
                    "description": "Rate of CR/CRh is defined as the percentage of participants achieving a CR or CRh at any time post-treatment.",
                    "timeFrame": "Up to 4 years and 9 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase 1: Plasma Concentration of Bleximenib",
                    "description": "Plasma concentration of bleximenib will be reported.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 1 and 2: Overall Response Rate (ORR)",
                    "description": "ORR is based on investigator-determined responses and is defined as the percentage of participants who achieve any response.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 1 and 2: Duration of Response (DOR)",
                    "description": "DOR will be calculated among responders from the date of initial documentation of a response to the date of first documented evidence of relapse, as defined in the disease-specific response criteria, or death due to any cause, whichever occurs first.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 1 and 2: Time To Response (TTR)",
                    "description": "TTR is defined for the responders as the time from the date of the first dose of bleximenib to the date of the first documented response.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Event-free survival (EFS)",
                    "description": "EFS is defined as the time from the date of first dose of study treatment to the date of treatment failure, relapse, or death due to any cause, whichever occurs first.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Overall survival (OS)",
                    "description": "OS is defined from the date of first dose of study treatment to the date of death due to any cause.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Measurable Residual Disease (MRD) Negativity Among Participants Achieving CR/CRh/CRi",
                    "description": "MRD-negative rate is defined as the percentage of participants who are MRD-negative at any timepoint after the first dose of bleximenib in the responders.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "description": "An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A Serious AE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Number of Participants Reporting Transfusion Independence",
                    "description": "Transfusion independence is defined as independence from red blood cells (RBC) and platelet transfusions during any 56-day interval after receiving study treatment.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Maximum Plasma Concentration (Cmax) of Bleximenib",
                    "description": "Cmax is defined as maximum plasma concentration.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Time to Reach the Maximum Concentration (Tmax) of Bleximenib",
                    "description": "Tmax is defined as time to reach the maximum concentration.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Area Under the Plasma Concentration-time Curve (AUC) from Time T1 to T2 of Bleximenib",
                    "description": "AUC t1-t2 is defined as area under the plasma concentration-time curve from time t1 to t2.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Area Under The Curve Over a Dosing Interval (AUCtau) of Bleximenib",
                    "description": "AUCtau is defined as area under the curve over a dosing interval.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Apparent Clearance (CL/F) of Bleximenib",
                    "description": "CL/F is defined as a measure of the rate at which a drug got metabolized or eliminated by normal biological processes.",
                    "timeFrame": "Up to 4 years and 9 months"
                },
                {
                    "measure": "Phase 2: Apparent Volume of Distribution (V/F) of Bleximenib",
                    "description": "V/F is defined as a theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.",
                    "timeFrame": "Up to 4 years and 9 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nPhase 1:\n\n* Relapsed or refractory (R/R) acute leukemia and has exhausted, or is ineligible for, available therapeutic options\n* Participants greater than or equal (\\>=)12 and less than (\\<) 18 years of age with a body weight of \\>= 40 kg are only eligible for the Phase 1 adolescent cohort\n* Acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 gene (NPM1) or nucleoporin 98 gene or nucleoporin 214 gene (NUP98 or NUP214) alterations\n\nPhase: 2\n\n* Participants greater than 18 years are eligible\n* Must have had an initial diagnosis of acute myeloid leukemia (AML) per the WHO 2022 classification criteria.\n* AML harboring KMT2A-r (gene rearrangement/translocation) or NPM1 mutations only\n\nFor Both Phase 1 and 2:\n\n* Pretreatment clinical laboratory values meeting the following criteria: (a) Hematology: white blood cell (WBC) count less than or equal to (\\<=) 20\\*10\\^9/liter (L) and renal function; Estimated or measured glomerular filtration rate greater than or equal to (\\>=) 50 milliliter per minute (mL/min) per four variable modified diet in renal disease (MDRD) equation\n* Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2. Adolescent participants only: Performance status \\>=70 by Lansky scale (for participants less than \\[\\<\\]16 years of age) or \\>=70 Karnofsky scale (for participants \\>=16 years of age)\n* A participant of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment\n* A participant must agree to all the following during the study and for 90 days after the last dose of study treatment: (a) wear a condom when engaging in any activity that allows for passage of ejaculate to another person; (b) not to donate sperm or freeze for future use for the purpose of reproduction. In addition, the participant should be advised of the benefit for a partner to use a highly effective method of contraception as condom may break or leak\n\nExclusion Criteria:\n\n* Acute promyelocytic leukemia, diagnosis of Down syndrome associated leukemia or juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria\n* Active central nervous system (CNS) disease\n* Prior solid organ transplantation\n* QTc according to Fridericia's formula (QTcF) for males \\>= 450 millisecond (msec) or for females \\>= 470 msec. Participants with a family history of Long QT syndrome are excluded\n* Exclusion criteria related to stem cell transplant: a. Received prior treatment with allogenic bone marrow or stem cell transplant \\<=3 months before the first dose of study treatment; b. Has evidence of graft versus host disease; c. Received donor lymphocyte infusion \\<=1 month before the first dose of study treatment; d. Requires immunosuppressant therapy (exception: daily doses \\<=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement)\n* Prior cancer immunotherapy within 4 weeks prior to enrollment or blinatumomab within 2 weeks prior to enrollment. Additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "12 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Contact",
                    "role": "CONTACT",
                    "phone": "844-434-4210",
                    "email": "Participate-In-This-Study@its.jnj.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Janssen Research & Development, LLC Clinical Trial",
                    "affiliation": "Janssen Research & Development, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "University of California Irvine Medical Center",
                    "status": "COMPLETED",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "University of California San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Norton Cancer Institute",
                    "status": "COMPLETED",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40207",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "NYU Langone Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "MD Anderson",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Medical College of WI at Froedtert",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                },
                {
                    "facility": "Monash Medical Centre",
                    "status": "RECRUITING",
                    "city": "Clayton",
                    "zip": "3168",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.91667,
                        "lon": 145.11667
                    }
                },
                {
                    "facility": "Royal Perth Hospital",
                    "status": "RECRUITING",
                    "city": "Perth",
                    "zip": "6000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.95224,
                        "lon": 115.8614
                    }
                },
                {
                    "facility": "Gold Coast University Hospital",
                    "status": "RECRUITING",
                    "city": "Southport",
                    "zip": "4211",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -27.96724,
                        "lon": 153.39796
                    }
                },
                {
                    "facility": "Institut Paoli Calmettes",
                    "status": "RECRUITING",
                    "city": "Marseille",
                    "zip": "13009",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.29551,
                        "lon": 5.38958
                    }
                },
                {
                    "facility": "CHU de Nantes hotel Dieu",
                    "status": "RECRUITING",
                    "city": "Nantes Cedex 1",
                    "zip": "44093",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.21725,
                        "lon": -1.55336
                    }
                },
                {
                    "facility": "Hopital trousseau- APHP",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75012",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie",
                    "status": "COMPLETED",
                    "city": "Pessac",
                    "zip": "33604",
                    "country": "France",
                    "geoPoint": {
                        "lat": 44.81011,
                        "lon": -0.64129
                    }
                },
                {
                    "facility": "Institut Universitaire du Cancer Toulouse Oncopole",
                    "status": "RECRUITING",
                    "city": "Toulouse",
                    "zip": "31059",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.60426,
                        "lon": 1.44367
                    }
                },
                {
                    "facility": "CHU Bretonneau",
                    "status": "RECRUITING",
                    "city": "Tours cedex",
                    "zip": "37044",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.38333,
                        "lon": 0.68333
                    }
                },
                {
                    "facility": "Hosp. Univ. Vall D Hebron",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hosp Clinic de Barcelona",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08036",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hosp Univ Fund Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Clinica Univ. de Navarra",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "zip": "31008",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Guy's and St Thomas' NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "SE1 9RT",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "The Christie Nhs Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Manchester",
                    "zip": "M20 4BX",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.48095,
                        "lon": -2.23743
                    }
                },
                {
                    "facility": "Oxford University Hospitals NHS Trust",
                    "status": "RECRUITING",
                    "city": "Oxfordshire",
                    "zip": "OX3 7LE",
                    "country": "United Kingdom"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency.\n\nAs noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",
            "url": "https://www.janssen.com/clinical-trials/transparency"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000054198",
                    "term": "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
                },
                {
                    "id": "D000000208",
                    "term": "Acute Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000007945",
                    "term": "Leukemia, Lymphoid"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M27585",
                    "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10951",
                    "name": "Leukemia, Lymphoid",
                    "relevance": "LOW"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "relevance": "LOW"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "relevance": "LOW"
                },
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M3564",
                    "name": "Acute Disease",
                    "asFound": "Acute Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T175",
                    "name": "Acute Lymphoblastic Leukemia",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3533",
                    "name": "Lymphoblastic Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "asFound": "Acute",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}